TheraCode to Acquire JPT Peptide Technologies | GenomeWeb

NEW YORK (GenomeWeb News) - German-based TheraCode, a wholly owned subsidiary of biotech firm BioNTech, has announced its intentions to buy JPT Peptide Technologies, also based in Germany, for €5 million ($6.8 million) in an all-cash deal.

JPT had been a wholly owned subsidiary of Jerini, which sold the company as part of its strategy to divest non-strategic businesses and focus on its core business, the commercialization of the drug icatibant (Firazyr) for the treatment of hereditary angioedema.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.